Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
SOPHiA GENETICS (Nasdaq: SOPH) announced significant leadership changes, hiring Peter Casasanto as Chief BioPharma Officer and Abhimanyu Verma as Chief Technology Officer. This move aligns with their strategy to enhance their footprint in the BioPharma sector. CEO Jurgi Camblong emphasized the importance of innovation in data-driven medicine. Peter brings over 15 years of life sciences experience, while Abhi has over 17 years in technology and data-driven drug development. Their expertise aims to support the company’s goal of advancing healthcare through comprehensive data insights.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that CEO Dr. Jurgi Camblong and CFO Ross Muken will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. ET. The presentation will be accessible live and archived on their website. SOPHiA GENETICS is focused on data-driven medicine and operates the SOPHiA DDM™ Platform used by over 780 institutions worldwide.
SOPHiA GENETICS has launched the DEEP-Lung-IV clinical study (NCT04994795) to analyze multimodal real-world data for predicting immunotherapy responses in 4,000 patients with stage IV non-small cell lung cancer (NSCLC). This large-scale study encompasses approximately 30 sites across North America, Europe, and Latin America. The initiative seeks to identify new predictive biomarkers, enhancing patient stratification and treatment decisions. The company aims to generate actionable insights to improve clinical outcomes in NSCLC patients, leveraging its proprietary SOPHiA DDM™ Platform.
SOPHiA GENETICS (Nasdaq: SOPH) will host a joint symposium with GE Healthcare on December 1, 2021, at the RSNA Annual Meeting in Chicago. The event, focused on advancing data-driven medicine, will explore multimodal digital health data integration using AI-powered analytics. This follows a recent Master Alliance Agreement between the two companies, aiming to enhance collaboration in healthcare solutions, particularly in digital oncology and radiogenomics. The partnership is expected to accelerate the adoption of SOPHiA's platform, enhancing healthcare delivery for cancer patients worldwide.
Balderton Capital has launched its largest-ever fund of
SOPHiA GENETICS (Nasdaq: SOPH) reported a robust 45% year-over-year revenue growth for Q3 2021, reaching $10.4 million. The company executed a Master Alliance Agreement with GE Healthcare to enhance oncology initiatives, expanding its market presence. Total recurring platform customers rose to 375, with a net dollar retention rate of 137%. Despite a net loss of $21.2 million or 35 cents per share, the company anticipates full-year revenue exceeding $40 million, indicating at least 41% growth for 2021.
SOPHiA GENETICS SA (Nasdaq: SOPH) has enhanced its SOPHiA DDM Universal Whole Exome platform with the integration of Agilent's SureSelect Human All Exon v8. This new bioinformatic workflow streamlines analysis from sample to variant report, supporting both germline and cancer applications. Key features include reduced turnaround time, multiple variant detection, tailored analytics for Agilent data, and a comprehensive gene coverage. The solution aims to accelerate research in rare and inherited diseases, making data-driven medicine more accessible.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in several upcoming investor conferences, including the Credit Suisse 30th Annual Healthcare Conference on November 11, the Piper Sandler 33rd Annual Healthcare Conference starting November 22, and the Evercore ISI HealthCONx Conference on November 30. Investors can access live and archived presentations through the company's Investors section on their website. SOPHiA GENETICS focuses on data-driven medicine, utilizing its cloud-based SOPHiA DDM™ Platform in over 780 institutions worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) announced it will report Q3 financial results on November 10, 2021, before the market opens. Management will host a webcast at 8:30 a.m. ET to discuss results, business advancements, and future outlook. The SOPHiA DDM™ Platform, their cloud-based SaaS solution, is utilized by over 780 institutions globally, aiming to set data-driven medicine as a standard. The live audio will be available on the company’s Investors section of the website, with an archived replay afterwards.
SOPHiA GENETICS (Nasdaq: SOPH) has launched the SOPHiA Clinical Exome Solution v3, which enhances probe design and detection capabilities for investigating Mendelian diseases. This application combines a capture-based target enrichment kit with the SOPHiA DDM™ platform, achieving over 90% analytical sensitivity for CNV detection. Enhanced probe design allows for improved detection of rare disorders across the mitochondrial genome and 280 known disorder-causing genomic locations. This innovation aims to streamline data analysis and improve institutional resource efficiency.